三阴性（雌激素、孕激素受体与HER-2均为阴性）乳腺癌（TNBC）是具有特殊的生物学行为及临床病理特征的一个乳腺癌亚型。TNBC 对化疗敏感，化疗是可手术以及晚期TNBC病人的主要治疗方法，紫杉类和铂类药物方案可能更为有效，但尚无标准化疗方案。近年来，靶向药物成为TNBC治疗研究的热点，也是未来的研究方向。

Choosing and evaluation of chemotherapy regimens in multimodality therapy of triple negative breast cancer          XU Bing-he. Breast Disease Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing 100021，China
Abstract    Triple negative (estrogen receptor, progesterone receptor and HER-2 are all negative) breast cancer (TNBC), a subgroup of breast cancer, has distinct biological, clinical and pathologic characteristics. TNBC is sensitive to chemotherapy which is main therapeutic method for early and metastatic TNBC. Taxanes or platinum-based chemotherapy may be more effective for TNBC. However, there are still no standard chemoterapeutic regimens. In recent years, target agents have become hotspot of study and direction of future study.